Cargando…

Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis

PURPOSE: This study aimed to investigate the value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in predicting early immunotherapy response of immune checkpoint inhibitors (ICIs) in patients with advanced or metastatic non-small-cell lung cancer (NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Tao, Zhang, Lianghui, Peng, Rui, Yue, Chao, Huang, Lingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713836/
https://www.ncbi.nlm.nih.gov/pubmed/36466905
http://dx.doi.org/10.3389/fimmu.2022.1014063
_version_ 1784842098411831296
author Ling, Tao
Zhang, Lianghui
Peng, Rui
Yue, Chao
Huang, Lingli
author_facet Ling, Tao
Zhang, Lianghui
Peng, Rui
Yue, Chao
Huang, Lingli
author_sort Ling, Tao
collection PubMed
description PURPOSE: This study aimed to investigate the value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in predicting early immunotherapy response of immune checkpoint inhibitors (ICIs) in patients with advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS: A comprehensive search of PubMed, Web of science, Embase and the Cochrane library was performed to examine the prognostic value of (18)F-FDG PET/CT in predicting early immunotherapy response of ICIs in patients with NSCLC. The main outcomes for evaluation were overall survival (OS) and progression-free survival (PFS). Detailed data from each study were extracted and analyzed using STATA 14.0 software. RESULTS: 13 eligible articles were included in this systematic review. Compared to baseline (18)F-FDG PET/CT imaging, the pooled hazard ratios (HR) of maximum and mean standardized uptake values SUV(max), SUV(mean), MTV and TLG for OS were 0.88 (95% CI: 0.69-1.12), 0.79 (95% CI: 0.50-1.27), 2.10 (95% CI: 1.57-2.82) and 1.58 (95% CI: 1.03-2.44), respectively. The pooled HR of SUV(max), SUV(mean), MTV and TLG for PFS were 1.06 (95% CI: 0.68–1.65), 0.66 (95% CI: 0.48-0.90), 1.50 (95% CI: 1.26-1.79), 1.27 (95% CI: 0.92-1.77), respectively. Subgroup analysis showed that high MTV group had shorter OS than low MTV group in both first line group (HR: 1.97, 95% CI: 1.39-2.79) and undefined line group (HR: 2.11, 95% CI: 1.61-2.77). High MTV group also showed a shorter PFS in first line group (HR: 1.85, 95% CI: 1.28-2.68), and low TLG group had a longer OS in undefined group (HR: 1.37, 95% CI: 1.00-1.86). No significant differences were in other subgroup analysis. CONCLUSION: Baseline MTV and TLG may have predictive value and should be prospectively studied in clinical trials. Baseline SUV(max) and SUV(mean) may not be appropriate prognostic markers in advanced or metastatic NSCLC patients treated with ICIs. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=323906, identifier CRD42022323906.
format Online
Article
Text
id pubmed-9713836
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97138362022-12-02 Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis Ling, Tao Zhang, Lianghui Peng, Rui Yue, Chao Huang, Lingli Front Immunol Immunology PURPOSE: This study aimed to investigate the value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in predicting early immunotherapy response of immune checkpoint inhibitors (ICIs) in patients with advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS: A comprehensive search of PubMed, Web of science, Embase and the Cochrane library was performed to examine the prognostic value of (18)F-FDG PET/CT in predicting early immunotherapy response of ICIs in patients with NSCLC. The main outcomes for evaluation were overall survival (OS) and progression-free survival (PFS). Detailed data from each study were extracted and analyzed using STATA 14.0 software. RESULTS: 13 eligible articles were included in this systematic review. Compared to baseline (18)F-FDG PET/CT imaging, the pooled hazard ratios (HR) of maximum and mean standardized uptake values SUV(max), SUV(mean), MTV and TLG for OS were 0.88 (95% CI: 0.69-1.12), 0.79 (95% CI: 0.50-1.27), 2.10 (95% CI: 1.57-2.82) and 1.58 (95% CI: 1.03-2.44), respectively. The pooled HR of SUV(max), SUV(mean), MTV and TLG for PFS were 1.06 (95% CI: 0.68–1.65), 0.66 (95% CI: 0.48-0.90), 1.50 (95% CI: 1.26-1.79), 1.27 (95% CI: 0.92-1.77), respectively. Subgroup analysis showed that high MTV group had shorter OS than low MTV group in both first line group (HR: 1.97, 95% CI: 1.39-2.79) and undefined line group (HR: 2.11, 95% CI: 1.61-2.77). High MTV group also showed a shorter PFS in first line group (HR: 1.85, 95% CI: 1.28-2.68), and low TLG group had a longer OS in undefined group (HR: 1.37, 95% CI: 1.00-1.86). No significant differences were in other subgroup analysis. CONCLUSION: Baseline MTV and TLG may have predictive value and should be prospectively studied in clinical trials. Baseline SUV(max) and SUV(mean) may not be appropriate prognostic markers in advanced or metastatic NSCLC patients treated with ICIs. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=323906, identifier CRD42022323906. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9713836/ /pubmed/36466905 http://dx.doi.org/10.3389/fimmu.2022.1014063 Text en Copyright © 2022 Ling, Zhang, Peng, Yue and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ling, Tao
Zhang, Lianghui
Peng, Rui
Yue, Chao
Huang, Lingli
Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
title Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
title_full Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
title_fullStr Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
title_full_unstemmed Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
title_short Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
title_sort prognostic value of (18)f-fdg pet/ct in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713836/
https://www.ncbi.nlm.nih.gov/pubmed/36466905
http://dx.doi.org/10.3389/fimmu.2022.1014063
work_keys_str_mv AT lingtao prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis
AT zhanglianghui prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis
AT pengrui prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis
AT yuechao prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis
AT huanglingli prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis